April 17, 2017 / 8:23 PM / 3 months ago

BRIEF-Rigel submits NDA to FDA for fostamatinib in chronic itp

1 Min Read

April 17 (Reuters) - Rigel Pharmaceuticals Inc:

* Rigel submits new drug application to fda for fostamatinib in chronic itp

* Rigel Pharmaceuticals Inc- company expects to receive notification regarding acceptance of NDA by FDA in June 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below